Diagnostic Value of Circulating MicroRNAs for Middle Aged Coronary Artery Disease Patients: A Case-control StudyCorrespondence Address :
Dr. Wahid Ali,
Associate Professor, Department of Pathology, King George Medical University,
Chowk, Lucknow, Uttar Pradesh, India.
Introduction: Coronary Artery Disease (CAD) remains a major problem worldwide. New and useful biomarkers for early diagnosis are necessary. MicroRNAs (miR) are short, non-coding RNAs that post transcriptionally regulate gene expression through degradation and translational repression of mRNAs.
Aim: The current case-control study was designed to assess strength and relevance of diagnostic miR-126, 122 and Vascular Endothelial Growth Factor (VEGF) level in the diagnoses of angiographically proven CAD cases.
Materials and Methods: Circulating levels of miR-126 and miR122 and VEGF levels were measured in serum from 100 middle aged 46-58 years patients with CAD and 100 patients without CAD through quantitative real-time polymerase chain reaction (qRT-PCR) analysis.
Results: Circulating miR-122 level was significantly higher in CAD cases compared to control (1.60±1.06 and 0.93±0.43, p=0.001), however miR-126 was significantly lowered in CAD cases compared to control (0.82±0.51 and 1.01±0.47, p=0.02). Circulating VEGF level was significantly higher in CAD cases compared to control (182.97±156.49 and 105.49±103.88, p=0.02). Circulating miR-122, 126 and VEGF level did not show any association with demographic and clinical parameters. Area Under the Curve (AUC) for circulating miR-122, 126 and VEGF were 0.700, 0.644 and 0.649 with sensitivity and specificity of 66.67%, 56.41%, 61.18% and 70%, 60% and 64%, respectively. The combined diagnostic efficacy of miR-122 and 126 showed higher sensitivity and specificity.
Conclusion: Circulating miR-122 and 126 might be novel, noninvasive biomarkers for early diagnosis of CAD. Further exposition of the role of miR-122, 126 and VEGF in the progression of CAD will add to the understanding of the disease process leading to a new diagnostic approach. However, further studies on larger patient cohorts are required to validate the findings.
Biomarker, Coronary disease, Real time PCR
Date of Submission: Jul 29, 2020
Date of Peer Review: Oct 07, 2020
Date of Acceptance: Dec 02, 2020
Date of Publishing: Mar 01, 2021
• Financial or Other Competing Interests: As declared above
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Aug 01, 2020
• Manual Googling: Nov 02, 2020
• iThenticate Software: Feb 23, 2021 (19%)
ETYMOLOGY: Author Origin
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)